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Abstract: Cystic fibrosis (CF) is a common genetic disease caused by a mutation in the 
cystic fibrosis transmembrane conductance regulator gene (CFTR). Mutations within this 
gene inhibit the function of the chloride ion channels across epithelial membranes. This 
leads to the formation of thick mucus within the lung airways of CF patients. Therefore, 
the CF lung becomes an excellent environment for bacterial colonization. S. aureus is the 
first pathogen to colonize the lungs and tends to persist throughout the lives of CF 
patients. S. aureus is known for its ability to develop resistance against antibiotics. 
Antibiotic resistance is one of the biggest problems faced in medicine today. This study 
aims to detect and characterize the resistance of S. aureus obtained from CF patients of 
various age groups to a panel of clinically relevant antibiotics. Based on findings from 
previous studies, there are nine antibiotic resistance genes in S. aureus that have been 
correlated with CF patients. Using PCR amplification, we checked if any of these 
resistance genes are present in the CF isolates. In addition, we performed antibiotic 
susceptibility tests to determine if these isolates exhibit a resistant phenotype. Minimum 
inhibitory concentrations (MICs) of each antibiotic to each isolate were determined to 
further confirm resistance.  In conclusion, the presence of resistance genes and 
susceptibility to antibiotics differ among CF patients. CF isolates showed both 
susceptibility and resistance to the tested antibiotics, but the percentage of resistant 
isolates was higher. The interesting finding was that resistance to antibiotics, in some 
isolates, did not correlate with the presence of resistance genes. This study expands our 
understanding of S. aureus as a CF pathogen and its resistance within the CF lung. This 
will aid in enhancing treatment options for CF patients to help them live longer and more 
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Cystic fibrosis (CF) is an autosomal recessive genetic disorder that is caused by a 
mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR) (O’Sullivan et 
al. 2009; Riordan et al. 1989). Cystic fibrosis is a common genetic disorder within the Caucasian 
population in the United States. The disease occurs in 1 in 2,500 to 3,500 Caucasian newborns; 
CF is less common in other ethnic groups (Cohen 2012). The CFTR gene is located on the apical 
membrane of epithelial cells in organs across the body, and it encodes for a phosphate-regulated 
chloride ion channel (Welsh and Smith 1993). CF presents itself pathologically as a multi-
systemic disease that can affect the lungs, salivary glands, pancreas, liver, kidneys, sweat ducts, 
and reproductive tract (Davis 2016). However, the lungs are most affected by the mutation and in 
turn, present the most challenges in acute and chronic management of the disease. To serve as a 
general prognosis of life span, the current guidelines utilize the health status of the lungs to 
determine the predicted life span as well as the quality of life for patients with CF (Cohen 2012).  
Unique to pulmonary disease as a sequel of CF, is the formation of hyper-viscous mucus 
in the lung airways of patients. Additionally, CF patients suffer from decreased mobility of the 
mucocillary escalator. Taken together, these faulted mechanisms provide for the over production 
of mucus, and the inability to eject, or cough up, mucosal secretions. This dynamic provides for 
an ideal environment allowing for bacterial and fungal growth and colonization. 
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Patients with CF are infected with a wide range of bacterial and fungal pathogens. Thus, CF is a 
polymicrobial infection (Razvi et al. 2009).  
Staphylococcus aureus is a major component of the pathogenic bacteria that colonize the 
CF lung. Specifically, S. aureus is frequently isolated from children. As such, it is considered to 
be a primary, first colonizers of the CF lung (Dasenbook 2010; Goss and Muhleback 2011). S. 
aureus dominates the bacterial population within the lungs during childhood, and remains the 
leading pathogen for the first decade of life of CF patients.  S. aureus remains present throughout 
the entire life span of CF patients and, despite treatment with antimicrobials, it is never 
completely eradicated. S. aureus was the leading cause of morbidity and mortality in the pre-
antibiotic era (Anderson, 1999). Yet, today, amidst the availability of antibiotics, which may or 
may not be helpful in the treatment of infections; S. aureus is a CF pathogen worth continued 
investigation due to the development of antibiotic resistance. The emergence of both nosocomial 
and community acquired methicillin-resistant Staphylococcus aureus (MRSA) is on the rise; 
MRSA infections observed in patients with CF are now more than 25% (CFF 2017). The 
detection of MRSA in the lungs of patients with CF is associated with poor prognosis 
(Dasenbrook 2010).  Nosocomial acquired MRSA refers to the acquirement of MRSA in a 
specific location such as hospital settings, given that MRSA was not present prior to 
hospitalization. In contrast, community acquired MRSA refers to the acquirement of MRSA 
outside of a hospital setting or the presence of MRSA on time of admission.  
S. aureus in the context of a CF pathogen is poorly studied as most research efforts are 
focused on Pseudomonas aeruginosa, simply the dominant pathogen in adulthood (CFF 2017). 
Consequently, research efforts devoted to studying the childhood and adolescent stages of CF are 
scarce. Therefore, efforts within this study are focused on obtaining CF samples from all age 
groups and building a repository that can be used for research purposes related to CF infections. 
Antibiotic resistance is a major concern within the medical community today. Furthermore, S. 
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aureus infections are difficult to treat and are rarely eradicated due to antibiotic resistance. The 
aim of this study was to detect and characterize antibiotic resistant S. aureus isolates obtained 
from CF patients of various age groups. This was accomplished by: evaluating resistance to 
antibiotics by determining minimum inhibitory concentrations (MICs) of clinically relevant 
antibiotics; and profiling resistance genes by looking for the presence or absence of antibiotic 
resistance genes. Overall, the hypothesis of this study was that S. aureus isolates from adult 






REVIEW OF LITERATURE 
 
I. Cystic Fibrosis  
Etiology of CF:  
Cystic fibrosis (CF) is the single most common, yet lethal genetic disorder. The name 
“cystic fibrosis” came from an autopsy of two young children who died because of this disease 
due to the formation of fibrosis, or buildup of connective tissue, with cysts localized in the 
pancreas (Anderson 1938). Since the first account of CF, it is now known to be an autosomal 
recessive disorder that mainly affects the Caucasian ethnic population (Cohen 2012). CF is 
caused by various mutations in the cystic fibrosis transmembrane conductance regulator gene, 
CFTR.  Currently, there are approximately 2000 mutations of CFTR that are cited, all of which 
allow for the onset of CF pathologies. However, the most common CFTR mutation is ΔF508 
(Riordan et al. 1989). It is approximated that in the United States alone, 30,000 individuals are 
currently living with CF, and about 1,000 new cases are diagnosed each year (CFF 2017).  
The CFTR: 
CFTR is located on the long arm of chromosome 7 and it encodes for a phosphate 
regulated chloride ion channel. CFTR is located on the apical membrane of epithelial cells in 
organs across the body, thus CF is a multi-systemic disease (Rommens et al. 1989; 
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Welsh and Smith 1993). The two major systems that are affected in CF are the lungs and 
the gastrointestinal tract. That is due to bacterial infections in the lungs that eventually deteriorate 
lung function and the altered transport of electrolytes across the GI tract that lead to insufficient 
enzyme production and fibrosis. The CFTR protein allows chloride ions to pass through epithelial 
cells that produce mucus; water follows this gradient of chloride ions making the mucus thin 
(Rafeeq 2007). When mutations occur within CFTR, it results in the formation of hyper-viscous 
mucus in the lung airways due to the inhibition of chloride ion transportation across the epithelial 
membranes. Therefore, water is drawn into the lumen leading to the accumulation of dehydrated 
thick mucus and the impairment of mucocillary clearance (Donaldson and Boucher 2003). The 
blockage of the lung airways with mucus causes damage to the airway walls and inevitably 
fibrosis develops. Further, airway colonization and infection with a diverse group of pathogens 
occurs with these faulted mechanisms that will eventually lead to decreased pulmonary function 
(Cohen 2010).  
Pulmonary Disease:  
In healthy individuals, the lungs and airways are sterile environments, despite the 
presence of viruses and bacteria in the air that is routinely respired. This sterility is maintained by 
lung defenses that function to clean the airways of healthy individuals by coating the airways 
with a thin layer of airway surface liquid (ASL). ASL contains periciliary sol and mucus gels that 
move toward the mouth via ciliary beating (Wine 1999). ASL also consists of proteases and 
antiproteases, oxidants and antioxidants, as well as antibiotics and antibodies (McWilliams 1996). 
Collectively, the lung airways are indefinitely cleaned by the actions of these components along 
with mucocillary clearance and mechanical coughing (Wine 1999). 
CF pulmonary disease starts in lung airways that are normal and healthy at the time of 
birth; however, these lungs become gradually diseased due to the formation of mucus plugs in the 
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airways (Martens 2011). The patterns seen in CF pulmonary disease are distinctive, the smaller 
lung airway infections are considered universal, impossible to clear, and lethal (Wine 1999). 
Airway colonization occurs with diverse microorganisms followed by clinical manifestations of 
evident infection with common CF pathogens such as Pseudomonas aeruginosa, Staphylococcus 
aureus, Haemophilus influenzae, and Burkholderia cepacia. CF pulmonary disease tends to be of 
highest severity in the upper lobes of the lungs (Cohen 2010; Wine 1999). The increased severity 
of CF in the upper lobes of the lungs is due to bronchiectasis, which is the recurrent inflammation 
in CF that leads to the thickening of the walls of the lung airways, preventing mucus clearance 
(Redondo et al. 2016). 
The Microbial Diversity in CF:  
Earlier studies of CF microbiome assumed that a limited diversity of pathogens were 
present in the lung, of which only a few species led to the deterioration of lung function. These 
pathogens included: P. aeruginosa, S. aureus, H. influenza, and B. cepacia complex (Gilligan 
1991). Therefore, most antibiotic treatments were administered based on the presence of these 
species in the lungs of patients with CF (Ramsey 1996). As culturing techniques advanced and 
sequencing became more available, the overall understanding of the microbial community of CF 
has changed. Presently, it is no longer regarded as an infection due to a single pathogen rather it is 
known as a polymicrobial infection (Guss et al. 2011; Sibley et al. 2008).  
Major Pathogens in CF:  
The formation of thick mucus in the CF lung airways creates an ideal environment for 
bacterial growth and colonization. That is due to the ability of bacteria to grow and multiply 
anaerobically while trapped by the thick mucus in the lung airways (Boucher 2002).  It is 
observed that the initial bacterial infections occur shortly after the time of birth. Individuals with 
CF are exposed to repeated invasions by a wide flora of opportunistic pathogens, thus CF is 
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classified as a polymicrobial infectious disease (Lyczak 2002). Infants and young children are 
typically infected with S. aureus and H. influenzae. Adolescents and adults are more likely to be 
infected with P. aeruginosa (Jain and Smyth 2012). 
H. influenzae is regularly found in the lower airways in young children around the age of 
one. It is important to know that H. influenzae in CF is non-typeable, meaning that immunization 
against H. influenzae type b in childhood does not protect against this infection. The role that this 
pathogen plays in CF pulmonary infection is not understood yet (Gibson et al 2003). 
S. aureus is the most common pathogen found in young children aged between 11 and 15 
years. In the past decade, S. aureus infections have become a major concern due to the rise of 
methicillin resistant S. aureus (MRSA). That is because MRSA infections are difficult to 
eradicate once they establish in the airways of patients with CF (Guss and Muhleback 2011). S. 
aureus as a CF pathogen will be discussed in more detail towards the end of this chapter.  
P. aeruginosa is the most commonly studied CF pathogen as it is reported to infect 
approximately 50% of adolescent patients and 80% of adult patients. Most patients with CF are 
infected with different genotypes of P. aeruginosa this suggests that the source of the infection is 
environmental, however that is still under investigation (Gibson et al. 2003). Chronic infections 
with P. aeruginosa tend to occur in patients within the mid-twenty years of life. P. aeruginosa is 
an important CF pathogen due to its ability to adapt in the CF lung and has been described as 
being capable of causing severe lung dysfunction (Folkesson et al. 2012).  
The Burkholderia cepacia complex, BCC, has recently become considered a prominent 
CF pathogen. Within the recent years, the life expectancy of patients with CF has increased, 
which permitted for BCC to be detected in about 10% of adult CF patients (Guatam 2011). BCC 
infections last for months or years and lead to severe pulmonary disease and cause death within a 
short amount of time. This has been attributed to the spread of BCC from person-to-person and 
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the poor outcome following lung transplantation (Chaparro et al, 1998). But such as any other CF 
pathogen, patients react to BCC infections differently and it is possible that some patients’ 
clinical status will not be affected by BCC infections (Guatam 2011). Managing CF patients with 
BCC infections is very challenging because BCC is resistant to most antibiotics. In addition, CF 
patients can acquire BCC infections from the environment or other CF patients, which led to the 
establishment of control procedures to prevent the spread of BCC.  Patients infected with BCC 
are segregated from all other CF patients and are advised to keep their distance to prevent 
unintentional spreading of BCC (Guatam 2011).  
Current Treatments for CF:  
CF differs among patients in severity and even symptoms. As a result, treatment options 
are specific to the needs of individual patients. As mentioned above, CF affects multiple organ 
systems. CF patients receive a combination of therapies to combat infections, support organ 
functionality, and as a result help them lead more productive lives. Currently, these therapies 
include antimicrobials to target bacterial infections, mechanical loosening of secretions, improved 
nutrition, and consistent exercise (CFF 2017).  
Airway Clearance Techniques (ACTs): Mechanical loosening of the hyper-viscous 
mucus that forms in the lungs of patients with CF is a method that helps in clearing the lungs and 
airways by coughing/huffing. Patients are advised to consult their respiratory therapist to choose 
the best technique to clear their airways. ACTs are easy to perform as a daily routine (CFF 2017).  
Enzyme Supplements: As described before, thick mucus accumulates in the CF lungs. 
Similarly, the pancreas of patients with CF produces thick mucus blocking the release of 
digestive enzymes. Therefore, the majority of CF patients take enzymes before they consume 
their meals. Typically, enzyme supplements are in capsule form and they are taken orally. 
Enzyme capsules start to work 45-60 minutes after they are taken. Taking these enzymes is 
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critical for the health of patients as not doing so may lead to poor digestion causing gas and pain. 
Also, improved lung function has been correlated with higher body weight (CFF 2017).  
CFTR Modulator Therapies: These therapies are meant to correct the defect in the CFTR 
protein. The exact mechanism through which these modulators work is not fully explained. As 
mentioned before, there are many different CFTR mutations and the modulators designed so far 
are only effective in patients with specific mutations (CFF 2017).  
Currently, two modulators have been approved for use by the FDA: Ivacaftor for children 
under the age of 6 years and having G551D mutation, a rare mutation (Rafeeq 2017; CFF 2017). 
This modulator has been very successful and shown an overall increased quality of life for 
patients. Recently, the FDA expanded its use to include other mutations as well as children 
between the ages 2 and 5 years. This therapy is not effective against ΔF508, the most common 
mutation, due to the decreased availability of the protein. This therapy is also expensive, and that 
is a limiting factor for its use. Another FDA approved CFTR modulator is Lumacaftor, which 
showed positive results in the ΔF508 mutation. This modulator showed increased transportation 
of the CFTR protein to the proper location, but no correction of the underlying functional 
impairment was noticed. Also, no improvements of respiratory exacerbation rates were seen 
(Rafeeq 2017; CFF 2017). 
Preventing and Controlling Lung Infections: CF patients are more likely to develop 
bacterial infections due to the buildup of thick mucus in the lung airways. These infections can be 
short-term known as acute infections or exacerbations, or long-term known as chronic infections. 
Antibiotics are used to treat infections caused by bacteria. The actions of antibiotics either kill the 
bacterial pathogen known as bactericidal antibiotics or inhibit its growth known as bacteriostatic 
antibiotics. Many bacterial infections in the CF lung can be treated with antibiotics. Antibiotics 
can be taken orally, inhaled, or intravenously (CFF 2017). Patients with CF usually take 
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antibiotics on a daily basis. Antibiotics are classified into classes that dictate their mechanism of 
action. Antibiotics can inhibit bacterial cell wall synthesis or function; inhibit protein synthesis, 
or inhibit nucleic acid synthesis or function. The list below showcases the antibiotics most 
commonly prescribed to patients with CF:  
The Beta-lactams: Beta-lactam antibiotics are structural homologs of the beta-lactam 
ring. Their mode of action is the inhibition of cell wall synthesis by targeting penicillin-binding 
proteins, PBPs, which are a group of enzymes located in the cell membrane and are involved in 
the peptidoglycan cross-linking of the bacterial cell wall.  These enzymes include transpeptidases 
and carboxypeptidases that bind beta-lactam antibiotics, penicillin binding proteins, PBP, 
(Heesemann 1993; Yocum et al. 1980). Beta-lactam antibiotics used for the treatment of CF 
patients include: amoxicillin, methicillin, oxacillin, nafcillin, cloxacillin, dicloxacillin, 
cabenicillin, ticarcillin, piperacillin, mezlocillin, azlocillin, ticarcillin, and tazobactam. All of 
these antibiotics are prescribed for the treatment of bacterial infections caused by S. aureus and P. 
aeruginosa (CFF 2017).  
The Aminoglycosides: Aminoglycoside antibiotics mode of action is the inhibition of 
protein synthesis. This is achieved by the binding of the antibiotic to the aminoacyl side of the 
16S rRNA within the 30S ribosomal subunit. This leads to a misreading in the genetic code and 
inhibits the translocation step of protein synthesis. Therefore, elongation fails to occur due to 
disruption of the mechanisms for ensuring translational accuracy. Aminoglycosides are usually 
bactericidal against aerobic gram-negative bacilli (Davis 1987). Aminoglycosides used to treat 
CF patients include tobramycin, amikacin, and gentamicin. Primarily, these pharmaceuticals 
target P. aeruginosa infections (CFF 2017).  
The Macrolides: Macrolide antibiotics mechanism of action can be observed in the 
process of the inhibition of protein synthesis; antibiotics in this class bind irreversibly to the 50S 
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subunit of the bacterial ribosome leading to the inhibition of translocation of tRNA during 
translation (Mazzeri et al. 1993). Macrolides used for CF patient treatment include erythromycin, 
clarithromycin, and azithromycin. These pharmaceuticals are utilized to target infections caused 
by S. aureus (CFF 2017). Azithromycin has an anti-inflammatory activity and it can prevent loss 
of lung function in CF patients. Azithromycin is now part of the routine CF care even if 
individuals are not infected with susceptible bacteria (Cohen 2010).  
Other antibiotics prescribed for treating infections in the CF lung include: cephalosporins 
to treat S. aureus and P. aeruginosa infections; Sulfa to treat P. aeruginosa and MRSA. 
Tetracyclines were previously used to treat P. aeruginosa infections and now they are used to 
treat S. aureus and some B. cepacia infections; quinolones for P. aeruginosa infections; 
vancomycin for S. aureus and MRSA infections; linezolid for MRSA and some mycobacteria 
infections; imipenem and meripenem for both S. aureus and P. aeruginosa infections; aztreonam 
for P. aeruginosa infections; and colistimethate for S. aureus and P. aeruginosa infections (CFF 
2017).  
The Problem of Antibiotic Resistance: 
 
As mentioned above, patients with CF are regularly treated with a combination of 
antibiotics that are taken daily to help them fight against a plethora of bacterial infections. With 
the excessive use of antibiotics, bacterial pathogens may develop resistance to the antibiotics. 
Resistance to antibiotics means that the pathogens are no longer affected by the mechanism of 
action provided by the drug. Typically, the increased use of antibiotics leads to a higher 
frequency of resistance development against the antibiotics among pathogens. This may even 
result in the development of bacterial strains that are resistant to several antibiotics, known as 
multi-drug resistant bacteria and those are very difficult to treat (Cystic Fibrosis Trust, UK 2017).  
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Antibiotic resistance is a natural phenomenon and it can be attributed to several factors 
that are either natural (develop without human action) or caused by the actions of humans. 
Bacteria naturally produce antibiotics and use them against other bacterial species. This leads to 
natural selection for resistance to antibiotics (Devel and Dermody 1991). Fungus, bees, and many 
other species also synthesize natural antimicrobial peptides. However, the more serious cause of 
antibiotic resistance is the overuse of antibiotics by humans. The more bacteria are exposed to 
antibiotics, the more likely they will develop resistance toward these antibiotics. Bacteria can 
acquire resistance to antibiotics using two mechanisms: The first mechanism is through a genetic 
mutation, which allows the bacteria to produce chemicals that render the antibiotics ineffective. 
Other mutations modify the cellular components that the antibiotics are designed to target. For 
example, some mutations change the binding affinity of the antibiotic by modifying the binding 
site; some mutations block the binding site of the antibiotic; and other mutations lead to the 
formation of efflux pumps that expel the antibiotic out of the cell and prevent it from reaching its 
target (Dever and Dermody 1991). The second mechanism that bacteria can use to acquire 
resistance is through obtaining resistance from another bacterium. There are several mechanisms 
for this type of resistance acquisition. The simplest way is through conjugation; in this process the 
bacteria are able to transfer genetic information, including resistance genes, from one bacterium 
to another. Resistance genes transferred via conjugation are found on plasmids and transposons. 
Another mechanism is through phage or viruses that infect bacteria. Viruses can transmit 
resistance genes among bacteria by obtaining resistance genes from the first bacterium and 
injecting them into a new bacterium that they attack, this process is known as transduction. 
Bacteria are also able to acquire resistance genes from their surrounding environment due to their 
ability to uptake naked or free DNA. Once bacteria uptake this free DNA, they can incorporate it 
into their genome and use it for their advantage. If the newly obtained DNA contains resistance 
genes, then, in turn, a beneficial evolutionary trait is possessed by the bacteria increasing odds of 
survival within the environment or in the presence of antibiotics (Dever and Dermody 1991).   
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In CF pulmonary disease, the problem of antibiotic resistance is a major concern when it 
comes to managing bacterial infections that eventually lead to a reduction in lung function. Major 
CF pathogens such as P. aeruginosa and S. aureus including MRSA have been named as a public 
health threat by the World Health Organization, WHO, due to their high rate of antimicrobial 
resistance. Multiple drug resistance is common among these pathogens. Multiple drug resistance, 
MDR, is defined as the resistance of species of microorganisms to multiple antimicrobial drugs. 
MDR species are considered a public health threat as they have resistance to multiple antibiotics 
and are difficult to treat (Magiorakos et al. 2011).   
Staphylococcus aureus: 
S. aureus is a Gram-positive non-motile coccoid bacterium and it is the primary 
pathogenic species in the Staphylococci genus. S. aureus is a commensal bacterium and it is 
usually found on skin surfaces and mucosal membranes. S. aureus grows best in saline 
environments and this characteristic explains its presence in the normal flora as 20% of the 
population is colonized by S. aureus, 60% are occasional carriers, and 20% of the population 
never carries it (Kluytmans 1997). S. aureus has a great potential of becoming pathogenic due to 
its localization in the nasal epithelium and in tissues beneath the epidermis. S. aureus is a major 
pathogen causing both sepsis and endocarditis. It also causes osteoarticular, epidermal, joint, and 
medical device-related infections (Otto 2010). 
Virulence Factors: S. aureus exhibits a wide range of virulence factors that allow it to 
colonize tissues causing damage and disease to the host. These virulence factors also promote the 
ability of S. aureus to attach and adhere to surfaces, evade immune system recognition, and 
produce toxins that harm the host (Justyna 2011). The attachment of a pathogen to a surface is the 
initial step in the development of infection. Accordingly, S. aureus initiates the process of 
colonization by utilizing adherence factors, termed adhesins. Adhesins are proteins attached to the 
S. aureus peptidoglycan via covalent bonds. These adhesins attach to the host extracellular matrix 
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in a specific manner (Foster and Hook 1998). Major S. aureus adhesins are staphylococcal protein 
A (SpA), clumping factor (Clf) A and B, fibronectin-binding proteins A and B (FnbpA and 
FnbpB), and collagen-binding protein (Foster and Hook 1998; Lowy 1998).  
S. aureus employs various mechanisms to evade both innate and acquired immunity. The 
majority of S. aureus strains produces and secretes anti-inflammatory molecules that protect them 
from the host innate immune system. Modified membrane lipids, surface polymers, and other 
components of the cell wall of S. aureus play a role in evading recognition by the immune system 
(Fedtke 2004). Biofilm formation is an important strategy that S. aureus utilizes to evade immune 
system recognition and also to inactivate antimicrobial molecules and phagocytes (Gotz 2002). S. 
aureus also secretes an array of toxins that cause severe biological damage to the host and often 
lead to cell death. The production and release of toxins by S. aureus also serves as a mechanism 
to escape elimination by the host immunity (Otto 2014).  The toxins produced by S. aureus 
include: cytotoxic toxins, hemolysins (α, β, and γ), toxic shock syndrome toxin, enterotoxins, and 
exfoliative toxins A and B (Justyna 2011).  
Epidemiology of Resistance Genes in S. aureus: 
 Incidence and Prevalence: According to the CFF Patient Registry, the prevalence of S. 
aureus infections in the lungs of CF patients increased steadily in the past 25 years. In 2015, S. 
aureus was isolated from respiratory tract cultures from 70.6% of CF patients. The prevalence of 
S. aureus infections is the highest among children and patients below the age of 18 years; the 
highest prevalence of MRSA infections occurs in patients between the ages 10 and 30 years 
(Cystic Fibrosis Foundation 2015). The outcome of MRSA infections tends to be worse than 
MSSA infections in patients with CF. MRSA clones were first reported in the 1960’s in a British 
hospital and rapidly spread from there (Jessen et al. 1969 and Parker 1970). The mecA gene is the 
gene responsible for methicillin resistance and it is found in all MRSA strains. The mecA gene is 
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part of a mobile genetic element designated as Staphylococcal cassette chromosome mec, 
SCCmec (Katayma et al. 2000). Currently, four different SCCmec elements have been 
characterized and their sizes range from 21 to 67 kb (Hiramatsu et al. 2001). Epidemiologic 
studies on SSCmec, attribute the emergence of MRSA clones as a result of horizontal gene 
transfer from related Staphylococci species of the mec gene into MSSA clones.  
 In addition to methicillin resistance, resistance against macrolide antibiotics is common 
among S. aureus clinical isolates. Unlike methicillin resistance, a number of genes confer 
resistance to macrolide antibiotics as well as lincosmide and streptogramin B antibiotics, MLSB. 
These resistance genes confer resistance in Staphylococci using a variety of mechanisms. The erm 
genes, which stand for erythromycin ribosomal methylase, include the ermA, ermB, ermC, and 
ermT genes, confer resistance to MLSB antibiotics by methylation of the ribosomal RNA target 
site. The msrA gene also confers resistance to MLSB antibiotics in Staphylococci by encoding for 
a macrolide efflux pump; this gene was first identified in S. epidermidis. Gerard et al. investigated 
the relative frequency of each of these MLSB resistance genes in 294 S. aureus clinical isolates. A 
percentage of 88% of these isolates contained at least one of the erm genes. Resistance was 
mainly due to the presence of the ermA gene, as this gene was detected in 63.2% of the isolates. 
The ermC gene was also high in prevalence among these isolates and it was the single gene 
detected in 25% of the S. aureus isolates. The detection of resistance due to msrA was more 
frequent in coagulase-negative Staphylococci than in S. aureus, as it was present in 14.6% in 
coagulase-negative Staphylococci and 2.1% in S. aureus. The prevalence of other resistance 
genes encoding for MLSB resistance was more frequently present in coagulase-negative 
Staphylococci. Therefore, studies indicate that resistance to MLSB antibiotics in Staphylococci is 
mainly due to the presence of two variants of the erm genes depending on the type of 
Staphylococci, whether it is coagulase positive or negative, as well as the methicillin 
susceptibility pattern, susceptible or resistant. The ermA gene was present in 57.6% of MRSA 
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strains and 5.6% in MSSA strains. While, the ermC gene was present in 4.9% of MRSA strains 
and 20.1% of MSSA strains (Gerard et al. 1999).  
  Resistance to aminoglycoside antibiotics is widespread among Staphylococci species. S. 
aureus becomes resistant against aminoglycoside antibiotics by producing genes that inactivate 
the aminoglycoside modifying enzymes, AMEs. These genes are encoded on plasmids or 
transposons. The most prevalent AME in Staphylococci clinical isolates is reported to be the 
bifunctional enzyme, acetyltranferase and phosphotransferase AAC(6’)/APH(2”), which is 
encoded by the aac(6’)/aph(2”) genes (Nurittin et al. 2006). Studies reported that this gene is 
responsible for aminoglycoside resistance in MRSA isolates as it was present in 66% of the 
isolates (Nurittin et. Al 2006). The prevalence of other aminoglycoside resistance genes was 
lower, as the aph(3’)-Illa gene was only present in 8% of MRSA isolates. Schmitz et al. 1999, 
and Choi et al. 2003, also reported that aac(6’)/aph(2”) was the most prevalent resistance gene 
among S. aureus clinical isolates. It is important to note that occurrence of AME genes is 
correlated with the presence of the mecA gene encoding for methicillin-resistance. The 
simultaneous presence of at least one AME gene with the mecA gene was detected in 72% of S. 

















I. Cystic Fibrosis Patient Samples 
I.a. Collection of Sputa Samples  
 Sputum was collected from patients at the Oklahoma Cystic Fibrosis Clinic at the OU 
Children’s Hospital in Oklahoma City, Ok. The nursing staff collected the samples in 50 mL 
sterile conicals and provided the following information with each sample: the patient’s age, 
gender, and diagnosed health condition upon sample collection. Health condition was described 
as either: healthy, not ill, acutely ill, no exacerbation, or exacerbation. Each patient was assigned 
an ID tag that is formulated from the date of the collection and a letter, which is given for the 
order of the patient, i.e. collection on 02/11/2017 from the first patient would be labeled as 
21117A. The sputum was immediately struck onto nutrient and selective media by using a sterile 
cotton swab to dip into the sample and, in a zigzag pattern, inoculate the media. Samples were 
incubated for 72-96 hours at 37°C. A remaining volume of 150 uL of sputum was placed in a 
cryovial containing 50% glycerol. If sputum remained, two 150 uL aliquots were placed in an 
Eppendorf tube with equal amounts of Zymo DNA/RNA shield. Genomic DNA and RNA were 
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extracted from these tubes using the corresponding Zymo extraction kits (ZymeResearch). 
Extracted and purified RNA was then stored at -80°C, and extracted and purified gDNA was then 
stored at 4°C. It is important to note that all sputum samples were frozen down on dry ice during 
the transport from the clinic located in Oklahoma City to Stillwater; following arrival, all samples 
were stored long-term at -80°C.  
I.b. Freezer Stocks 
 The nutrient and selective plates of media included the differential and selective medium, 
mannitol salts agar (MSA), which was prepared according to manufacturer’s instructions 
(Criterion).  Plates were incubated, inverted, at 37°C for 72-96 hours. Recoverable bacterial 
growth from all eight media, including MSA, was scraped from the agar with 10% skim milk. 
Bacterial suspensions in skim milk were then moved into corresponding cryovials. Cryovials 
were labeled with the patient’s identification tag, the media, and the date the freezer stock was 
made. All cryovials were stored long term at -80°C.  
II. Antibiotic Susceptibility Tests 
II.a. Preparations of Antibiotics 
 All antibiotics used in this study were received as powders (Gold Biotechnology, USA); 
they were accurately weighed and dissolved in the appropriate diluents to yield the required 
concentrations. Stock concentrations were 0.05 g/mL; 1:10 dilutions were made for the working 
concentrations from the stock to yield working concentrations of 0.005 g/mL.  
• Methicillin, diluted in H2O, Gold Biotechnology, USA; 
• Erythromycin, diluted in 95% ethanol, Gold Biotechnology, USA; 
• Kanamycin, diluted in H2O, Gold Biotechnology, USA; 
• Gentamicin, diluted in H2O, Gold Biotechnology, USA; 
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• Streptomycin, diluted in H2O, Gold Biotechnology, USA; 
• Tobramycin, diluted in H2O, Gold Biotechnology, USA.  
 
II.b. Kirby-Bauer Disc Diffusion Method 
The susceptibility of S. aureus to antibiotics was determined by the Kirby-Bauer disc 
diffusion method. Using a sterile cotton swab applicator, a lawn of the S. aureus clinical isolate 
was struck onto Mueller Hinton Agar (ThermoFisher Scientific, USA) plates to cover the entire 
surface of the plate. Hand punched filter discs (diameter size = 6mm) were added onto the 
bacterial lawn, equidistant from one another. A volume of 10uL of antibiotics (methicillin, 
erythromycin, kanamycin, tobramycin, gentamycin, and streptomycin), were added onto the filter 
discs at a concentration of 0.005 g/mL. The susceptibility was interpreted based on the diameter 
of the zones of clearance, read in millimeter, after 24 hours of incubation at 37°C.  The measured 
zones of clearance were then recorded. Results obtained from this method are referred to as 
phenotypic resistance profiles and they were compared to the genotypic resistance profiles 
obtained by PCR amplification of antibiotic resistance genes specific to S. aureus.  
II. c. Minimum Inhibitory Concentrations (MIC) 
 The minimum inhibitory concentrations (MIC), which are a measurement of the 
minimum concentration of antibiotics required for the inhibition of visible growth of bacteria. 
MICs were determined by the broth microdilution method following the guidelines of the Clinical 
and Laboratory Standards Institute (CLSI).  Two-fold serial dilutions of methicillin, 
erythromycin, and kanamycin were prepared in a 100uL volume in 96-well microtiter plates 
starting at a concentration of 0.05 g/mL. The dilution series included the antibiotic diluents H2O 
and 95% ethanol as controls. A volume of 900 uL of the bacterial culture was then added to each 
well. The MIC was interpreted by visual means. The lowest concentration of antibiotic, in which 
20	  
	  
there was a lack of visible growth of the bacterial isolate was recorded following an overnight 
incubation, shaking at 220 RPM, 37°C.  
 
III. Extraction of Genomic DNA and Gene Amplification (PCR) 
III.a. Extraction of Genomic DNA 
 S. aureus isolates were grown overnight shaking at 37°C, 220 RPM in 5 mL of Luria 
Bertani (LB) broth (Fisher Bioreagents, USA). The overnight cultures were centrifuged at 3,000 
RPM for 10 minutes. Supernatant was discarded from the sample and the pellets were used for 
genomic DNA, gDNA, extraction using the ZymoResearch Fungal/Bacterial DNA Miniprep kit 
(ZymoResearch). The extracted gDNA was then used as a template for Polymerase Chain 
Reaction (PCR) to assess for antibiotic gene presence in the tested S. aureus isolates.  
III.b. Gene Amplification (PCR) 
 Extracted and purified genomic DNA was used as a template in all PCR reactions to 
check for the amplification of the nine antibiotic resistance genes chosen for investigation within 
the scope of this study: mecA, ermA, ermB, ermC, ermT, msrA, aphA3, aadC, and acaaphD. PCR 
was also used to amplify the 16S rRNA gene and the rpoB gene. The enzyme used in all PCR 
reactions was Taq 2X Maser Mix (BioLabs, USA). PCR was carried out using an Eppendorf 
Mastercycler.  
The thermal-cycling conditions were standardized for the amplification of resistance 
genes and 16S rRNA and produced optimum results: initial denaturation at 95°C for 30 sec, 30 
cycles of denaturation at 95°C for 30 sec, annealing for 1min at 68°C, and extension at 68°C for 5 
min. The annealing temperature was adjusted for the amplification of the rpoB primers to 55°C.  





Table 1: Primer sequences used for PCR 











ermB  (Jung et 
al. 2009) 
Macrolide 
Forward: TTGGATATTCACCGAACACTAGGG  
Reverse: ATAGACAATACTTGCTCATAAGTAACGG  
































(Xu et al. 2012) 













III.c. Visualization of PCR Products 
 PCR products were separated in 2% Agarose gels (Biotechnology Grade AMRESCO, 
USA), stained with ethidium bromide, and visualized using the Gel Doc system, VWR Variable 
Intensity UV Transilluminator.  Amplicons were compared to known product sizes for gel 
interpretations. Results obtained from the amplification of antibiotic resistance genes are referred 
to as genotypic resistance profiles and they were compared to the phenotypic resistance profiles 
obtained by the Kirby-Bauer disc diffusion method.  
IV. Resistance to Rifampicin  
IV.a. Rifampicin-resistant Mutants  
 S. aureus isolates were struck from the freezer stock onto MSA plates containing 0.2 g 
rifampicin/L (Gold Biotechnology, USA) and incubated, inverted for 24 hours at 37°C. If growth 
was present, such indicated that the isolate was resistant to rifampicin. If isolates were susceptible 
to rifampicin (no growth), then they were driven to resistance by the following protocol adapted 
from Schaaf et al. Susceptible S. aureus isolates were grown overnight in 5 mL of Trypticase Soy 
Broth (TSB) (BD, USA) shaking at 37°C, 220 RPM. The overnight cultures were normalized to 
1.0 at an optical density of 600 nm. Then, the isolates were plated onto Trypticase Soy Agar 
(TSA) plates containing 100 mg rifampicin/L. Plates were incubated, inverted for 48 hours at 
37°C. Growth indicated that these isolates developed rapid mutations to resist rifampicin present 
in the medium. All isolates, already resistant or induced to resistance, were used to study 
mutations within the rpoB gene. The mutable region of the rpoB gene was amplified using PCR. 
The PCR products were cleaned and concentrated using the Zymoclean Gel DNA Recovery Kit 
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(Zymoresearch, USA) and sent for sequencing at the OSU Biochemistry and Molecular Biology 






FINDINGS   
 
I. Introduction to Collection of Sputa Samples from Cystic Fibrosis Patients  
 
An established interest exits in building and maintaining a repository of CF sputa samples 
and bacterial isolates in which easy access can be obtained. Access is granted to not only the 
Department of Microbiology and Molecular Genetics at Oklahoma State University, but 
additionally, other laboratory groups that are interested in research related to CF disease and its 
pathogens. The creation and maintenance of this repository became possible through the 
collaboration with the Cystic Fibrosis Clinic at the University of Oklahoma (OU) Children’s 
Hospital in Oklahoma City, OK. Sputa samples were collected from patients with CF by the 
nursing staff. Then, these sputa samples were struck onto a total of eight different types of 
selective and nutritional media to allow for the recovery of a wide range of the microbial diversity 





In order to study antibiotic resistance in S. aureus, the isolation of S. aureus from CF 
sputa samples was essential. Mannitol Salt Agar (MSA) was used for the selective isolation of S. 
aureus from sputum. MSA is highly selective for Staphylococci due to the high concentrations of 
NaCl (7.5%-10%). This elevated level of salt is inhibitory to the growth of most other bacterial 
species. MSA is also a differential medium for Staphylococci mannitol-fermentation; it contains 
the carbohydrate mannitol and the pH phenol red indicator that detects acid production by 
mannitol-fermenting Staphylococci. Since S. aureus is capable of mannitol-fermentation, it 
causes a color change in the medium, from red to yellow, due to the acid production and 
subsequent alteration of indicator, phenol red. S. aureus colonies appear yellow after growth on 
MSA plates. Other coagulase-negative Staphylococci do not cause a color change in the medium 
and grow pink/red colonies, allowing for easy visual identification.  To further confirm that the 
bacteria recovered from the MSA plates was indeed S. aureus, the 16S ribosomal RNA of random 
patient isolates were sequenced for verification and analyzed via the NCBI Standard Nucleotide 
BLAST.  
II. Results  
Most of the collected sputa samples came from adult patients over the age of 18 years.  
Therefore, there is a lack of samples from child and adolescent patients. Partly, this is due to the 
rejection of medical compliance of parents/legal guardians to have their children participate in a 
research study. However, since S. aureus is a dominant pathogen in children and remains present 
in the lungs of adult CF patients, mostly all of the collected samples contained S. aureus. It is not 
surprising that a few patients were colonized with more than one Staphylococcus species. This 
was indicated by the difference in colony morphology on MSA plates. Typically, a S. aureus 
colony on an MSA growth medium is yellow in pigmentation with round, convex, and creamy 
morphology. However, several patient isolates produced colonies on MSA medium with differing 
morphologies, yet yellow pigmentation.  
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Specifically, these colonies with different morphologies were selected and tested as 
separate isolates from the same patient. For example, patient 12315E produced 3 different colony 
morphologies on MSA, each one of these colonies became a separate isolate from that patient and 
named as 12315E(1), 12315E(2), and 12315E(3). Also, the presence of small red to pink colonies 
with little to no color change on MSA plates was observed among the patient isolates. 
Specifically, these colonies were suspected to be Staphylococcus epidermidis due to the lack of 
mannitol fermentation and subsequent lack of differing media and colony pigmentation. Yet, no 
16S sequencing was performed to further confirm the identity of these isolates. In order to 
increase the sample size, S. epidermidis isolates were used in the study and they were renamed as 
81414C epid.  
Table 2: Patient List 
Sputa Sample ID  Age Condition 
21116B 6 Not ill  
5814D 8 No exacerbation 
21116A 8 Not ill  
12116C 9 Not ill  
11614D 10 Not ill  
81414A 10 Not ill  
5814E 11 No exacerbation  
22714C 12 No exacerbation 
8714A 13 Acutely ill  
51514C 16 Exacerbation - does not feel ill  
2515D 17 No exacerbation  
6514A 19 Acutely ill  
5814G 20 No exacerbation 
51514D 20 Exacerbation  
6514D epid 20 No exacerbation 
22014D 21 Exacerbation  
12116B 21 Ill  
61214C 22 Ill 
61214C epid 22 Ill 
61214A 24 Ill 
73114A 25 Not ill  
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22714E 26 Exacerbation 
112014D 26 On antibiotics  
22714B 27 Exacerbation  
31314A 28 No exacerbation 
9414B 28 Not ill  
61214B 28 Exacerbation  
51514A 28 No exacerbation 
3614A epid 28 No exacerbation 
3614B epid 29 No exacerbation 
91715D 31  Not ill 
12315E (1) 31 Ill 
12315E (2) 31  Ill 
12315E (3) 31  Ill 
8714C 32 Not ill  
5814F 32 Exacerbation 
5814H 32 Exacerbation 
81414D epid 32 Confusing 
9414C 33 Ill 
3614C epid 38 Not acutely ill  
22014B 39 No exacerbation 
81414C epid 39 Not ill 
21915B 40 Not ill 
32014B 41 Not acutely ill  
32014B (1) 41 Not acutely ill  
32014B (2) 41 Not acutely ill  
 
Table 2 listed above is the sputa sample ID’s, ages, and health conditions of patients that 
were a part of this study. A total of 46 S. aureus isolates recovered from 41 CF patients were 
collected from February 2014 to December 2016. Of these samples, 7 isolates came from children 
(under the age of 12 years); 4 isolates came from adolescents (between the ages 12 and 17 years); 
and the remaining 35 isolates came from adults (over the age of 18 years). Table 2 is ordered 
according to age. Among these patients, only 1 adolescent and 6 adults were experiencing 




II. b. Growth on Mannitol Salt Agar 
As mentioned above, S. aureus isolates were selected for on MSA plates. S. epidermidis 
can also grow on MSA plates. The following figure shows the typical colony morphology and 




Figure 1: Colony morphology and pigmentation of Staphylococcus on MSA plates 
Part A in Figure 1 shows the growth of S. aureus on MSA. The yellow pigmentation is 
due to mannitol salt fermentation by S. aureus. Part B shows the growth of S. epidermidis on 
MSA. S. epidermidis does not ferment mannitol salts, therefore, no change in the color of the 
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II. c. 16S rRNA Gene 
The presence of the colony morphology and color change of agar upon growth of S. 
aureus on MSA medium is a good starting point as to identify the species of the bacterium by 
biochemical differential means. However, in order to proceed with this study, the sequencing of 
the 16S ribosomal RNA provided confirmation of species identity. The 16S rRNA is a component 
of the small 30S subunit in the prokaryotic ribosome and it is involved in the translation process 
of protein synthesis. The 16S rRNA gene is often used in phylogeny reconstruction due to the 
extremely slow rate of evolution in this region of the DNA. The 16S rRNA gene was amplified 
with PCR using oligonucleotide primers that are conserved throughout S. aureus strains.  
 
Figure 2: The amplification of 16S rRNA gene:  PCR amplification results of the 16S rRNA gene 
in S. aureus isolates and control strains ATCC 13525, PAO1, and H2O control.  
 Figure 2 shows the PCR amplification results of the 16S rRNA gene by S. aureus isolates 
obtained from CF patients’ sputa. ATCC 13525 is a S. aureus positive control strain; PAO1 is a 
P. aeruginosa strain used as a control to show that there is no contamination in the S. aureus 
isolates; and H2O was used as a negative control. The amplified products were sent for 
sequencing at the OSU Biochemistry and Molecular Biology Core Facility. Sequences were then 
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obtained and NCBI BLAST nucleotide was used to confirm the identity of S. aureus, results are 
shown in figure 3 below.  
 
Figure 3:Analysis of 16S rRNA sequences. The identification of isolates obtained from CF 
patients as S. aureus by analyzing the 16S rRNA gene sequences by NCBI nucleotide BLAST. 
As expected, upon analysis of the 16S rRNA gene sequences, obtained from PCR 
amplification, provided by the NCBI BLAST tool, the results demonstrate that the isolates were 
S. aureus (Figure 3).  
III. Introduction to Antibiotic Susceptibility Tests and MICs  
 Following the isolation and identification of S. aureus from CF patients, isolates were 
subjected to a survey of clinically relevant antibiotics. The goal was to characterize antibiotic 
resistance profiles of these patient isolates both phenotypically and genetically.  
For the phenotypic characterization, the Kirby-Bauer disc diffusion method was used to 
measure the sensitivity of bacteria to antibiotics. Each S. aureus isolate was struck on Mueller-
Hinton Agar plates, a non-differential medium, to create a lawn of bacteria that covers the entire 
plate. Antibiotic discs were added on top of the bacterial lawn, and then 10 uL of liquid 
antibiotics were applied onto the top of the discs at a concentration equal to 0.005g/mL as shown 
in figure 4 below. Susceptibility or resistance to antibiotics was determined by measuring the 





IV.a. Kirby-Bauer susceptibility test results 
 
Figure 4: Kirby-Bauer Susceptibility Test Results: Kirby-Bauer results of patients’ 22014D and 
22714C on Mueller-Hinton Agar plates. A. 22014D tested with GM, TOB, and STM; B. 22714C 
tested with GM, TOB, and STM. C. 22014D tested with MET, ERY, and KN; D. 22714C tested 
with MET, ERY, and KN.  
The Kirby-Bauer tests served as biochemical means to characterize sensitivity or 
resistance towards antibiotics. The diameters of the zones of clearance around the antibiotic discs 








ERY ERY KN KN 
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 Table 3: Resistance and Susceptibility of Staphylococci Isolates to Antibiotics  
Isolate (Patient ID) MET ERY KN TOB GM  STM  
31314A R R R R R R 
22014B 23 mm 26 mm R R R R 
22714B R R R R R R 
22714C 10 mm R R R R R 
22014D 15 mm R R R R R 
22714E 25 mm R R R R R 
9414B 20 mm 19 mm R 28 mm 21 mm 19 mm 
9414C 13 mm R R 21 mm 19 mm 23 mm  
8714C R 11 mm R 17 mm 10 mm R 
5814D 16 mm 27 mm R R R R 
5814F R R R R R R 
11614D 16 mm 27 mm R 29 mm 20 mm 19 mm 
51514C R R R R 9 mm R 
8714A R R R R R R 
2515D 16 mm 8 mm R 29 mm R R 
61214C  13 mm 10 mm  R R R R 
6514A R 11 mm R R 21 mm R 
61214B R R R R R R 
73114A 10 mm R R 20 mm R R 
5814G 20 mm 26 mm R 29 mm 31 mm R 
51514D R R R 28 mm R R 
91715D R R R 23 mm 9 mm R 
12116B R R R R 21 mm 11 mm 
51514A R R R R 25 mm 15 mm 
12116C 25 mm 27 mm R 20 mm 21 mm 19 mm 
21116A R 18 mm R 25 mm 29 mm 11 mm 
21116B R 13 mm R 26 mm 30 mm 10 mm 
112014D R R R R 26 mm 20 mm 
21915B 34 mm R 26 mm 29 mm 29 mm 11 mm 
32014B R R R R R R 
81414A 20 mm 28 mm R 21 mm 20 mm 14 mm 
3614A epid R R 19 mm 11 mm 35 mm 17 mm 
3614B epid 13 mm R 19 mm 19 mm 30 mm 11 mm 
3614C epid 20 mm R 16 mm 11 mm 31 mm 16 mm 
33	  
	  
32014B (1) R R R R 21 mm R 
32014B (2) R R R R 24 mm R 
5814H R R R R 25 mm R 
81414C epid 40 mm 19 mm 22 mm 23 mm 39 mm 13 mm 
61214C epid 11 mm R R R 30 mm R 
6514D epid R R R R 33 mm R 
81414D epid 19 mm R R R R R 
5814E 11 mm R 16 mm 16 mm 21 mm 18 mm 
12315E (1) 10 mm R 16 mm 16 mm 19 mm 20 mm 
12315E (2) 11 mm R 17 mm 18 mm 19 mm 21 mm 
12315E (3) 12 mm R 17 mm 16 mm 19 mm 20 mm 
61214A 11 mm R R R 30 mm R 
R = resistant. MET = methicillin; ERY = erythromycin; KN = kanamycin; TOB =  
tobramycin; GM = gentamycin; and STM = streptomycin. The diameter of the zone of clearance 
in susceptible isolates was measured and recorded in millimeters (mm). 
 
Based on the results obtained from the Kirby-Bauer susceptibility tests, it is evident that 
the majority of the S. aureus isolates exhibit resistance to the tested antibiotics of the same 
concentration. Resistance incidences provided by isolates were enumerated and divided by the 
total number of isolates tested (n=46) and multiplied by 100 to provide for an overall percentage. 
Values are portrayed on the table below summarizing both susceptibility and resistance of the 







Table 4: Percentages of S. aureus Isolates Resistant or Susceptible to a Panel of Six Clinically 
Relevant Antibiotics  
 
 Variability of S. aureus susceptibility to antibiotics can be observed from one patient 
isolate to another as demonstrated in Table 3. Some patients were susceptible and some were 
resistant to the same applied antibiotics. However, the percentage of resistant S. aureus isolates 
was higher than the susceptible isolates as depicted in Table 4. It can be observed that resistance 
to macrolide antibiotics yielded higher values compared to the beta-lactam and aminoglycoside 
antibiotics tested.  
IV. b. Minimum Inhibitory Concentrations (MICs) 
 As stated above, the Kirby-Bauer susceptibility tests were the initial step in 
characterizing resistance to antibiotics. To further confirm resistance, the minimum inhibitory 
concentrations (MIC) of methicillin, erythromycin, and kanamycin were determined for each S. 
aureus isolate. A single antibiotic was chosen to serve as a representative for the class of 
antibiotics to which they are classified: methicillin representing the beta-lactam antibiotics, 
erythromycin representing the macrolide antibiotics, and kanamycin representing the 
aminoglycoside antibiotics. MIC is a measurement of the lowest antibiotic concentration required 















using microtiter plates with two-fold dilutions of the antibiotics and inoculated with an equal 
bacterial inoculum (O.D.600 = 0.25), incubated shaking at 37°C, 220 RPM for 24 hrs. The MIC 
was recoded the following day as the lowest concentration of antibiotic with no visible growth. 
The MIC values for each isolate are presented in Table 5 and summarized in Figure 5 below.  
Table 5: Minimum inhibitory concentrations (ug/mL) of independently tested S. aureus isolates  
Patient Isolate Tag Methicillin Erythromycin Kanamycin 
31314A 31.25 62.5 N/A 
22014B 15.6 15.6 31.25 
22714B 125 125 62.5 
22714C 250 125 31.25 
2515D 0.488 15.6 15.6 
11614D 0.488 31.25 31.25 
6514A 62.5 125 125 
9414B 31.25 15.6 31.25 
8714A 125 N/A 62.5 
8714C 62.5 62.5 125 
61214B 62.5 0.244 3.91 
51514A 125 0.244 0.488 
51514C 31.25 31.25 31.25 
51514D 15.6 0.976 62.5 
5814H 7.81 7.81 125 
91715D 62.5 15.6 62.5 
12116B 125 15.6 N/A 
12116C 62.5 250 62.5 
112014D 125 N/A 250 
32014B(1) 125 250 62.5 
32014B(2) 31.25 3.91 62.5 
5814D 125 250 125 
5814E 31.25 250 250 
5814F 250 250 62.5 
73114A 125 N/A N/A 
61214B 3.91 250 250 
3614A 3.91 250 31.25 
3614B 62.5 250 15.6 
3614C 62.5 250 15.6 
5814G 62.5 250 N/A 





Figure 5: Antibiotic Minimum Inhibitory Concentrations  
The MIC data above demonstrates that resistance of these S. aureus isolates when 
challenged with methicillin, erythromycin, and kanamycin is quite high. In fact, it is considered to 
be very high compared to the published MIC ranges for methicillin, erythromycin, and 
kanamycin. (NCCLS 2004; Matynia 2005; Chakraborty 2011). The red asterisks indicate the 
approximate location of published ranges of MICs for these antibiotics from clinical isolates, also 
shown in Table 6 below.   
Table 6: Published MIC Ranges in S. aureus Clinical Isolates  
Antibiotic MIC Range 
Methicillin (MET) 
(NCCLS 2004) 
12.5 - > 100 ug/mL 
Erythromycin (ERY) 
(Matynia 2005) 
0.125 - > 16 ug/mL  
Kanamycin (KN) 
(Chakraborty 2011) 
> 64 ug/mL  
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V. Introduction to the Presence/Absence of Antibiotic Resistance Genes  
Cumulatively, Kirby-Bauer susceptibility tests along with the MIC data provide 
phenotypic characterization of the resistance profiles of the S. aureus isolates collected from CF 
patient samples. However, genetic profiling is monumental in the understanding of antibiotic 
resistance among S. aureus isolates. Nine antibiotic resistance genes encoding for resistance to 
the three classes of antibiotics included in this study were hypothesized to be present in S. aureus 
isolates, as these are correlated with antibiotic resistance in CF patients (Prunier 2002; 
Dasenbrook 2010; and Rahimi 2016). By utilizing PCR, genes were amplified with gene specific 
primers (Table 1) and visualized with gel electrophoresis. Presence of amplicons demonstrated 
the detection of an antibiotic resistance gene. These results validate the phenotypic resistance 
observed by isolates obtained by the Kirby-Bauer susceptibility tests. The presence of each 
resistance gene in each isolate is detailed in Table 7 below.   
VI. Results  
VI.a. Presence/Absence of Antibiotic Resistance Genes 
Each S. aureus isolate was tested for the presence of the nine resistance genes, which are 
specific for S. aureus. It is known that numerous resistance genes are produced by S. aureus; 
however, studies on CF indicated that the presence of these genes is associated with CF (Prunier 
2002; Dasenbrook 2010; and Rahimi 2016). Furthermore, these resistance genes are found in 
other bacterial species, and here we are looking at the genetic variants of these genes that 
exclusively exist in S. aureus, hence the word specific for S. aureus. S. aureus isolates that have a 
particular gene present during screening served as positive controls for subsequent analysis. The 
presence of an antibiotic resistance gene from a patient, which was amplified successfully, was 




Table 7: Presence or absence of antibiotic resistance genes in Staphylococci  
Isolate ID mecA  ermA  ermB ermC ermT msrA aphA3  aadC  aacaphD 
21116Bc +           +     
5814Dc +   +   + +       
21116Ac +           +     
12116Cc                   
11614Dc                   
81414Ac                   
5814Ec +                 
22714Cc +                 
8714At +                 
51514Ct + +               
2515Dt                   
6514Aa + +               
5814Ga                   
51514Da                   
6514Da -– 
epid 
+                 
22014Da +                 
12116Ba + +               
61214Ca – 
epid 
                  
61214Aa +                 
22014Ba             + +   
73114Aa +                 
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22714Ea                   
112014Da + +               
22714Ba + +               
31314Aa + +         + +   
9414Ba +             +   
61214Ba + +               
51514Aa + +   +           
3614Aa-
epid +                 
3614Ba-
epid 
+                 
12315Ea (1)                   
12315Ea (2)                   
12315Ea (3)                   
91715Da                   
8714Ca + +         +     
5814Fa + + +         +   
5814Ha + +               
81414Da -– 
epid +           +     
9414Ca + +               
3614Ca-
epid +                 
81414Ca – 
epid 
                  
21915Ba +           +     
32014Ba (1) +                 
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32014Ba (2)  + +               
Table is ordered according to age of patient at the time of collection of sputa sample. The 
superscripts indicate if the patient isolate is from a child, c, or a teenager, t, or an adult, a.  
 Table 7 demonstrates the results of PCR amplification when screened with nine antibiotic 
resistance genes in all of the S. aureus isolates. The (+) sign indicates that the corresponding gene 
was amplified from the purified gDNA from each correlating patient isolate provided by 
amplicon presence and size. Interestingly, not all of the isolates had resistance genes; 13 out of 46 
isolates completely lacked the presence of resistance genes. For example, isolates 11614D, 
61214C, and 81414A do not have any of the resistance genes. In contrast, 20 isolates had two or 
more resistance genes present, for example isolates 5814D and 5814F. From this data, it is 
evident that multi-drug resistance is present among S. aureus isolates recovered from CF patients. 
Table 7 also shows the results of PCR amplification of the resistance genes in 7 S. epidermidis 
isolates, 5 out of the 7 isolates carried the mecA gene encoding for resistance to methicillin. 
Isolate 81414D-epid also carried the aphA3 gene encoding for resistance to aminoglycoside 
antibiotics, such as gentamicin.  
 Each gene which was amplified from the template genomic DNA confers resistance to a 
certain class of antibiotics. For example, mecA confers resistance to the beta-lactam family of 
antibiotics, which functions to inhibit peptidoglycan growth and repair. The erm genes, or 
erythromycin ribosomal methylase genes, (ermA, ermB, ermC, and ermT) confer resistance to 
macrolide, lincosamides, and streptogramin B antibiotics by methylation of the ribosomal RNA. 
Thus, the pattern of resistance to these antibiotics is known as MLSB resistance.  Macrolide efflux 
pumps encoded for by the msrA gene can also cause resistance to MLSB antibiotics (Schmitz 
2000).  Resistance to aminoglycoside antibiotics is encoded by the aphA3, aadC, and aacaphD 
genes, which encode for aminoglycoside-modifying enzymes (Schmitz 2000).  For these reasons, 
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genes were enumerated for total percentages and used to create a comparative Table (Table 8) to 
demonstrate the variability in gene presence/absence amongst isolates.  
Table 8: Summary of the amplification of antibiotic resistance genes in S. aureus isolates  
 
As shown in Table 8 above, the mecA gene is present in the majority (70.45%) of S. 
aureus isolates recovered from CF sputa samples. The mecA gene encodes for resistance to beta-
lactam antibiotics such as commonly prescribed, penicillin or methicillin. Therefore, the presence 
of this gene in the majority of the S. aureus isolates is not surprising as the percentage of 
methicillin-resistant S. aureus (MRSA) among CF patients is on the rise. Typically, the presence 
of mecA provides enough evidence to classify a strain as being methicillin resistant. The presence 
of genes encoding for macrolide resistance came in the second place as 29.54% of isolates had 
the ermA gene present. Since this study includes 5 genes that encode for macrolide resistance, the 
presence of at least one gene is enough to characterize an isolate as having genotypic resistance. 
The same applies for the aminoglycoside resistance genes. Resistance to aminoglycoside 






























































which is a bifunctional enzyme (aaC/acaphD) that encodes for resistance to gentamicin, was 
never detected in our study as shown in Table 8. Although this gene was detected before in S. 
aureus clinical isolates (Matsua et al. 2003; Akpaka 2017). Therefore, the primers used in Table 1 
for the amplification of this gene should not be problematic since they were the same as the 
primers published in the study of Matsau et al. Gradient PCR was initially performed to 
determine the optimal conditions for the amplification of these genes. Therefore, S. aureus 
isolates in this study do not carry the aacaphD gene.   
VI. b. Phenotypic and genotypic resistance profiles  
 The detection of antibiotic resistance genes in S. aureus is an important tool used to 
understand the mechanisms of resistance that S. aureus may utilize in order to persist in the lungs 
of CF patients. Therefore, comparing the data generated from the phenotypic and genotypic 
studies will provide important information regarding the patterns of S. aureus resistance in CF 
patients. As mentioned above, if an isolate was resistant to a certain antibiotic in the Kirby-Bauer 
tests for example kanamycin, then it should also have at least one resistance gene that encodes for 
aminoglycoside resistance present, either aphA3, aadC, or aacaphD. As expected, most of the 
isolates’ phenotypic resistance profiles matched the genotypic profiles, near identically. Isolates 
showed phenotypic resistance on the Kirby-Bauer plates as well as genotypic resistance in the 
PCR amplification of the resistance genes.  
 The more interesting results were obtained when the phenotypic resistance profiles did 
not correspond with the genotypic resistance profiles. Meaning that some isolates showed 
resistance in the Kirby-Bauer tests, but when tested for the presence of antibiotic resistance genes, 
no resistance genes were detected by PCR. Some S. aureus isolates exhibited resistance for 
antibiotics yet they lacked the presence of the genes that encode for the resistance to these 
antibiotics. These results are extremely important in the understanding of antibiotic resistance 
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patterns of S. aureus inside the lungs of CF patients. There are many ways to explain the absence 
of these resistance genes in some of the isolates. Importantly, and as mentioned before, S. aureus 
produces a number of antibiotic resistance genes and not all of them are included in this study. 
Therefore, it is possible that these isolates lack the genes we tested for and carry other genes that 
encode for resistance. Another explanation could be the possibility of the PCR not being sensitive 
enough or the presence of mutations within the primer binding regions in these isolates, which 
will lead to negative PCR results (Whiley 2005; Stanhouders 2010). Also, if S. aureus lacks the 
genes that encode for resistance, then this could suggest that S. aureus is using another 
mechanism to acquire resistance in the CF lung. In order to summarize these findings, the 
genotypic and phenotypic profiles that were matching (both resistant) or were conflicting 
(resistance genes absent) were enumerated in Table 9 below.  
Table 9: Comparison of Kirby-Bauer susceptibility tests and PCR results  
 
Table 9 shows the isolates with matching resistance profiles, both genetic and phenotypic 
profiles are in agreement, and the isolates with non-corresponding resistance profiles. Since the 
majority of the S. aureus isolates had the mecA gene present, resistance to methicillin often 
















observed in macrolides and aminoglycoside. As shown in Table 9, aminoglycosides had the 
lowest percentage of detected resistance genes. However, in the Kirby-Bauer susceptibility test, S. 
aureus isolates showed resistance to antibiotics in the aminoglycoside class. Even though a high 
percentage of the S. aureus isolates had the macrolide resistance genes present, the number of 
isolates with non-corresponding resistance profiles were more than those that have both 
phenotypic and genotypic resistance.  
VI. c. Age and antibiotic resistance 
 Patients with CF are diagnosed at, or just after birth. It is known that S. aureus is the first 
pathogen to colonize the lungs of CF patients (Dasenbook 2010; Goss and Muhleback 2011). As 
mentioned before, it is often isolated from children. However, it remains a prevalent colonizer 
within the lungs of adult CF patients. Therefore, it is of interest to see if there is a correlation 
between the age of patients and antibiotic resistance. CF patients start receiving antibiotics to 
treat the chronic infections caused by S. aureus and other pathogens at a young age. By the time 
they reach adulthood, the pathogens in their lungs have been exposed to antibiotics for a long 
period of time. It can be speculated that the more pathogens are exposed to antibiotics, the more 




















Figure 6: The relationship between age of CF patients and the presence of antibiotic resistance 
genes. A: Total umber of antibiotic resistance genes present in each age group compared to the 
total number of patients in each age group.  B: The number of present resistance genes was 
normalized to the size of the pool from each age group.   
Part A in figure 6 above shows the number of S. aureus patient isolates (grey) and the 
number of antibiotic resistance genes detected in each age group (black). It is important to note 
that there is a lack of S. aureus isolates from children and adolescents because parents and legal 
guardians do not consent to study participation.  The total number of antibiotic resistance genes in 
each age group refers to the overall number of antibiotic resistance genes present among all 
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 The relationship between age and resistance cannot be fully understood due to the over-
representation of adults in the study compared to other age groups. However, in this data set, 
isolates from adult patients, on average per isolate, exhibit more resistance genes than isolates 
obtained from adolescents and children as shown in part B of figure 6. As previously mentioned, 
some isolates (n=19) had several resistance genes present. These isolates with more than 2 
resistance genes present were adults. That is, we can possibly state that S. aureus isolated from 
adult patients exhibits more resistance genes than S. aureus isolated from child or adolescent 
patients. Yet, this statement requires further confirmation with increased enrollment of child and 
adolescent patients.  It is true that as patients with CF age their health conditions worsen and the 
eradication of pathogens becomes more difficult. The increased presence of antibiotic resistance 
genes in S. aureus isolates associated with older age could be a way to explain this occurrence.  
VII.a. Introduction to rifampicin-resistant S. aureus Isolates  
 In the past decade, MRSA infections have increased in the United States and become 
even more of a serious threat. Beta-lactam antibiotics are typically used to treat S. aureus 
infections; however, when S. aureus is resistant to beta-lactam antibiotics, as in MRSA strains, 
the drug of choice is vancomycin, a glycopeptide antibiotic. Vancomycin treatment is often 
coupled with rifampicin; that is due to the poor tissue penetration of vancomycin as well as its 
slow bactericidal effect against some S. aureus strains (Deresinki 2009). In addition to 
methicillin, MRSA strains are resistant to multiple other antibiotics. More than 50% of MRSA 
strains are resistant to rifampicin (Voss et al. 1994). Rifampicin interacts with the beta subunit of 
the bacterial RNA polymerase, which is encoded by the rpoB gene (Aboshkiwa et al. 1995). 
Rifampicin resistance in S. aureus is caused by alterations in the target site that reduces the 
enzyme affinity for the antibiotic. Bacteria susceptible to rifampicin can undergo spontaneous 
one-step mutations to develop resistance. Rifampicin mutations are encoded by the Rif region, an 
81 base pair rifampicin-resistance-determining region in the rpoB gene (Goldstein 2014). Here, 
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we have amplified this highly mutable region of the rpoB gene by PCR and sequenced portions of 
rpoB from rifampicin-susceptible and resistant S. aureus CF isolates (Wichelhaus 1999). 
VII.b. Results  
 
Figure 7: Amplification and multiple sequence alignment of rpoB gene from S. aureus isolates: 
A. The highly mutable region of the rpoB gene in S. aureus and the location of primer binding 
49	  
	  
sites indicated by the blue arrows (not drawn to scale). B. Visualization of the amplification of 
rpoB gene from S. aureus isolates. C. Multiple sequence alignment of rpoB gene sequences 
showing locations of point mutations.  
Part A in Figure 7 above shows the region of the rpoB gene amplified with gene specific 
primers by PCR. This region is referred to as the hotspot region due to the high rate of mutation 
within it. The hotspot region in rpoB is between nucleotide base positions 1442 and 1451, the 
primers bind in positions 1233 (forward) and 1654 (reverse) producing an amplicon size of 460 
base pairs (Wichelhaus 1999). These PCR products were purified and sent for sequencing. A 
multiple sequence alignment of the rpoB sequences from 11 isolates, including 8 rifampicin-
susceptible isolates and 3 rifampicin-resistant isolates was generated. These sequences were also 
aligned with rpoB wild type sequences from S. aureus strains from the NCBI database.  
Table 10: Mutations within the rpoB gene in S. aureus isolates 
Isolate ID Nucleotide Mutation Amino Acid Substitution 
22014B CCC à TCC 464Pro à Ser  
22014B ACC à GCC 477Thr à Ala  
22014B ACG à GCG 473Thr à Ala  
22014C CAT à TGT 481His à Asn  
31314A ATT à ATC 471Ile à Ile  
31314A GGA à GAA 483Gly à Glu*  
61214B GGA à GTA 423Gly à Val*  
9414C CGC à CGA 458Arg à Arg  
51514A GGA à GTA 423Gly à Val*  
Novel mutations within the Rif region of the rpoB gene are indicated by an asterisk (*).  
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Table 10 shows the mutations detected in the amplified portion of the rpoB gene. Not all 
of the sequenced isolates contained mutations in this region, 6 out of 11 isolates had mutations. 
Typically, mutations in the rpoB gene are characterized by a single base pair change that leads to 
an amino acid substitution, as observed in this data set, excluding the two silent mutations. Isolate 
22014B, which is methicillin sensitive obtained from an adult patient with no exacerbations 
contained three point mutations. Isolate 31314A, which is methicillin-resistant obtained from an 
adult patient with no exacerbations possessed two point mutations. Both of these isolates were 
susceptible to rifampicin. The remaining 4 isolates had single point mutations and were a mix of 
rifampicin resistant and susceptible, all obtained from adults. Collectively, it can be inferred that 
the nature of the amino acid substitution affects the level of resistance. The most common amino 
acid substitutions in rpoB point mutations are 481His àAsn and LeuàSer. The common 481His 
à Asn substitution was detected in our data set and it is usually associated with low-level 
rifampicin resistance. The 464ProàSer, 481HisàAsn, 477AlaàThr, and 473AlaàThr 
substitutions were also previously detected in S. aureus isolates (Wichelhaus et al 1999; Aubry-
Damon 1998).  The rest of the mutations have not been previously reported in S. aureus isolates. 
Therefore, the detection of these mutations in our study is a novel finding. These mutations are 
designated by an asterisk (*) in Table 9 and include 483GlyàGlu amino acid substitution, and 
423GlyàVal amino acid substitution. The 423GlyàVal substitution occurred twice in our data 
set, therefore, further investigation is required to understand the significance of this mutation in 
terms of antibiotic resistance. Additionally, an increased sample size is needed to conduct a more 
thorough screening of mutations within the rpoB gene in S. aureus isolates obtained from 





Table 11: Mutations within rpoB and susceptibility to rifampicin and methicillin 
Isolate ID Mutation to rpoB Rifampicin MRSA or MSSA 
22014B Detected Resistant MSSA 
22014C Detected Resistant MSSA 
31314A Detected Resistant MRSA 
61214B Detected Resistant MRSA 
9414C Detected Sensitive MSSA 
51514A Detected Sensitive MRSA 
MRSA = methicillin resistant S.aureus; MSSA = methicillin sensitive S. aureus 
 Previous studies found that mutations occurring within the rpoB gene lead to rifampicin 
resistance and that was often associated with a higher level of methicillin and vancomycin 
resistance, respectively (Wichelhaus et al. 1999). However, no specific mutations were directly 
linked to this association. Table 10 shows that MRSA and MSSA are equally distributed among 
the patient isolates that had mutations within the rpoB gene in this study. Therefore, no 
generalizations about the association of rpoB mutations and higher MRSA incidents can be made 











Within the CF lung, a dynamic exists in which formation of the thick mucus in the lung 
airways creates an ideal environment for bacterial growth and colonization. Infections from 
bacterial pathogens begin shortly after birth. A wide range of pathogens are involved in the lung 
infections in patients with CF. Infants and children are typically infected with Staphylococcus 
aureus. S. aureus is the most common pathogen among young CF patients, however, it remains 
prevalent throughout the lives of CF patients and it is never completely eradicated. S. aureus is 
one of the most common agents in community acquired infections as well as nosocomial 
infections (Prabhakara et al. 2013). In addition, S. aureus has recently gained a lot of attention 
due to the increased occurrence of methicillin-resistant S. aureus (MRSA).  
 The native immune system is the first line of defense against S. aureus. The use of 
antibiotics is the second line of defense against S. aureus infections. It is suspected that the 
overuse and misuse of antibiotics led to the emergence of antibiotic resistant S. aureus strains. 
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 Antibiotics have been an effective treatment for CF lung infections; however, these 
treatments fail to completely eradicate the lungs of the pathogens (Fodor et al. 2012).  This is 
because CF pathogens tend to be highly adaptive within the CF polymicrobial community. S. 
aureus in particular employs several adaptive strategies including the development of antibiotic 
resistance. As mentioned above, S. aureus develops resistance to antibiotics either by genetic 
mutations or by acquiring resistance genes from another bacterium either by conjugation or 
transformation (Dever and Dermody 1991). S. aureus can also persist in the lung airways of 
patients due to phenotypic switching to a small colony variant form, also described as a persister 
phenotype. Persisters are basically colony variants that are dormant with a high level of resistance 
to antibiotics (Mitchell 2011; Yagci et al. 2013). Commonly utilized antibiotic therapy 
contributes to the selection of small colony phenotype, which is more frequently observed in 
older CF patients (Yagci et al. 2013). The formation of biofilms is also a factor that hinders the 
clearance of pathogens from the lungs. Biofilm formation is especially implicated, in regards to 
co-infection, by P. aeruginosa. However, recent advances in the molecular biology of 
Staphylococci allowed for the basic understanding of biofilm formation in Staphylococci such as 
S. aureus and S. epidermidis (Otto 2008).   
  The building of the repository of CF patient isolates allowed for studying S. aureus 
isolates from numerous CF patients of differing age groups and discrete health conditions. In 
general, the selection for S.aureus on MSA growth medium produced similar colony 
morphologies and pigmentations. However, S. aureus obtained from some patients produced 
colonies that were different in size and those were tested as separate isolates from that patient. It 
is possible for one patient to be infected with more than one strain of S. aureus. This was not very 
common among S. aureus in this study, but the strains that were phenotypically different 
responded to antibiotic challenges similarly. S. aureus strains isolated from CF patients have been 
shown to be diverse in many aspects including colony morphology (Sadowska et al 2002). 
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However, these variations are not very common as most CF patients are infected with 
phenotypically similar S. aureus. Our findings are in agreement with prior studies hypothesizing 
such (Yagci et al 2013). When we tested for the diversity of S. aureus isolates recovered from a 
single CF patient, there was not an observable difference in the size of the zones of clearance in 
the Kirby-Bauer susceptibility tests (See Appendix D).  S. aureus is the predominant 
Staphylococci species in CF lungs; however other species such as S. epidermidis have previously 
been identified in CF patients (Lyczak 2002). As such, S. epidermidis was isolated from CF 
patient samples, although, infrequently in comparison to S. aureus.  
 S. epidermidis is a skin colonizer that is not known to cause harm to the host. However, 
in the recent years, nosocomial infections caused by S. epidermidis have increased in frequency. 
Therefore, S. epidermidis is currently seen as an opportunistic pathogen. The rate of infectious S. 
epidermidis in hospital settings is almost as high as infections caused by S. aureus (Otto 2009). In 
regards to CF, S. aureus infections in the CF lung are far more studied and documented in 
comparison to S. epidermidis. That is due to several reasons including: 1. S. epidermidis was not 
thought of as an infectious agent until recently; 2. Even though S. epidermidis causes infections, 
these infections are not life threatening (Otto 2009); and 3. S. aureus has been reported to cause 
more potent infections in the CF lung than S. epidermidis (Hussain 2013). Including S. 
epidermidis in this study was not initially intended, as all the S. epidermidis isolates were 
included to only increase the sample size. However, the addition of these isolates to our study 
provided a deeper understanding of antibiotic resistance in Staphylococci.  
As mentioned in the results chapter, antibiotic susceptibility and the presence of 
antibiotic resistance genes were tested in 7 S. epidermidis isolates. Only 2 isolates were resistant 
to methicillin, and 6 out of the 7 isolates were resistant to erythromycin and gentamicin as shown 
in Table 3. Interestingly, the only resistance gene present in 5 out of the 7 isolates was the mecA 
gene, which encodes for methicillin resistance. The spread of antibiotic resistance genes in S. 
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epidermidis is frequent, and more importantly, resistance to methicillin is specifically high among 
clinical isolates and it is estimated to be between 75 and 90%, A study by Diekemia et al. in 2001, 
indicated that the frequency of methicillin resistance in S. epidermidis in clinical isolates is higher 
than that in S. aureus, which was estimated to be between 40 and 60%. One S. epidermidis isolate 
had the aphA3 resistance gene present, which encodes for resistance to aminoglycoside 
antibiotics. In addition to methicillin, S. epidermidis is known to have resistance to multiple other 
antibiotics such as gentamicin and erythromycin, which are aminoglycoside antibiotics (Rogers 
2008). Our findings are in line with previous studies regarding antibiotic resistance of S. 
epidermidis. Resistance to erythromycin and gentamicin was observed in our data set as indicated 
in Table 3. Although phenotypic resistance to methicillin was not observed in our data set, MICs 
for these S. epidermidis isolates were not measured in this study and the susceptibility observed 
by the Kirby-Bauer method is insufficient in determining whether these isolates are resistant or 
not, which will require further confirmation. The presence of the mecA gene among S. 
epidermidis clinical isolates has been well documented. In fact, studies indicated that the mecA 
resistance cassettes were transferred from S. epidermidis to S. aureus (Guo 2007; O’Gara 2007).  
Therefore, S. epidermidis serves as a reservoir for the transfer of resistance genes to improve the 
pathogenicity of S. aureus in human disease (Otto 2001).  
The susceptibility of S. aureus isolates to antibiotics differed from one patient to the 
other. The results obtained from the Kirby-Bauer susceptibility tests demonstrated that each S. 
aureus isolate is unique. Further, though all of these patients were infected with S. aureus, the 
strain and pathology is unparalleled. As such, it is hypothesized that many factors contribute to 
the uniqueness of CF infections, for example, a variety of factors such as different genes and 
biological pathways. Environmental factors also play an important role in influencing the 
progression of the disease infections especially because the environmental factors are difficult to 
assess (Amaral 2015). This explains why no two patient isolates were similar in terms of 
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susceptibility to antibiotics. For example, isolate 5814E was obtained from an 11-year-old with 
no exacerbation yet presented as susceptible to nearly all antibiotics, for the exception of 
erythromycin. Isolate 22714C originated from a 12-year-old patient with no exacerbation was 
resistant to all antibiotics and was only susceptible to methicillin. Even though these two isolates 
came from children with similar health conditions, the S. aureus infecting their lungs responded 
very differently to antibiotics.  In contrast, isolate 31314A came from a 28-year-old patient with 
no exacerbation was resistant to all of the antibiotics tested for in this study; as was the same for 
isolate 5814F that came from a 32-year-old patient experiencing exacerbation. These two S. 
aureus isolates were resistant to all antibiotics regardless of the health condition of the patient. 
Therefore, our findings agree with the notion of developing individualized treatments for CF 
patients as every individual with CF is unique and requires personal assessment to predict the 
severity of the infection and determine drug usage (Amaral 2015).  
 Resistance to macrolide antibiotics was the highest among all the isolates tested by the 
Kirby-Bauer disc diffusion method. The high rate of macrolide resistance among S. aureus 
isolates from CF patients has been documented since the 1990s. The percentage of macrolide 
resistant S. aureus recovered from CF patient was 53%, where resistance to other antibiotics was 
a lot lower: oxacillin at 13%, and gentamicin at 6% (n = 122) (Prunier et al. 2003).  The 
resistance to macrolide antibiotics has been reported to increase over the years while resistance to 
other antibiotics remains constant (Prunier et al 2003). In this study, the representative macrolide 
antibiotic was erythromycin, which is one of the three most commonly used macrolides along 
with clarithromycin and azithromycin. These macrolides are structurally similar, therefore, the 
development of resistance to one antibiotic will lead to a complete cross resistance between all 
macrolides (Phaff et al. 2006). According to NCCLS breakpoints, S. aureus with an MIC of 
erythromycin greater than 8 mg/mL is classified as resistant. The calculated MICs shown in table 
5 indicate that the majority of S. aureus isolates in our study are resistant to erythromycin. CF 
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patients receiving azithromycin for a prolonged period of time have an increased macrolide 
resistant S. aureus. Thus, physicians should be extremely careful when prescribing macrolides to 
CF patients, as the emergence of intrinsic resistance to macrolides in S. aureus is a potentially 
serious threat (Phaff et al. 2006).  
Research studies focused on the relationship between antibiotic susceptibility patterns 
and antibiotic resistance genes in S. aureus clinical isolates found that all erythromycin resistant 
isolates carried at least one of the macrolide resistance genes (Duran 2012; Schmitz et al. 2000). 
These studies, along with others, found that the ermA gene is the most prevalent macrolide 
resistance gene among S. aureus clinical isolates. In our data set, ermA, was present in 29.54% of 
S. aureus isolates (n=46). Similarly, ermA, was present in 21.5% of S. aureus clinical isolates 
collected from blood, wounds, pus, urine, and other sources in Turkey over a period of two years 
(n=298) (Duran 2012). Our findings are in line with previous studies that the ermA gene is the 
most prevalent macrolide resistance gene. However, these studies also found that the ermC gene 
is the second most prevalent among erythromycin resistant S. aureus isolates. Our data shows that 
the ermB gene is the second most prevalent among erythromycin resistant S. aureus isolates at 
4.55%, the ermC gene was present in 2.27% of the isolates. The prevalence of ermC seems to be 
higher in coagulase negative S. aureus isolates (Duran 2012); however, S. aureus coagulase 
production was not within the scope of this investigation.  
 Aminoglycoside antibiotics are widely used in the treatment of CF lung to target, 
specifically, infections caused by P. aeruginosa. As such, S. aureus is not typically treated with 
aminoglycosides. Nearly all S. aureus isolates in this study were resistant to kanamycin and 
streptomycin. This is not surprising, as these two antibiotics are not utilized for S. aureus 
infections. Initially, kanamycin was the only antibiotic representative from the aminoglycoside 
class included in this study. However, since all of the isolates in our study were resistant to 
kanamycin and high kanamycin resistance among S. aureus clinical isolates was previously 
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reported (Hauschild et al. 2008); expansion of the representative antibiotics from this class was 
performed to include streptomycin, tobramycin, and gentamicin. Tobramycin and gentamicin 
have similar properties and they are active in low concentrations against S. aureus. In fact, S. 
aureus is the only Gram-positive pathogen that tobramycin is active against. In general, the 
resistance against macrolide antibiotics was high, but when comparing individual patient isolates 
(Table 3), most isolates were susceptible to tobramycin and gentamicin and resistant to 
kanamycin and streptomycin. A study conducted on S. aureus clinical isolates that were also 
identified as MRSA showed that these isolates had a high level of resistance to kanamycin, 
tobramycin, and gentamicin (Rahimi 2016). Given that our data set contains MRSA strains, the 
high level of resistance to kanamycin is in agreement with these findings. However, S. aureus 
isolates in our study were susceptible to tobramycin and gentamicin as shown in Table 3. As 
such, the relationship between MRSA and resistance to tobramycin and gentamicin was not 
observed in our results.  
 As mentioned above, S. aureus gained a lot of attention in the past decade due to the 
increased emergence of methicillin-resistant strains, MRSA. Methicillin was first introduced in 
1959; methicillin resistant strains developed only 2 years after its introduction and were only 
found in hospital settings (Goss and Muhleback 2012). In 2001, MRSA was found in 2% of CF 
patients and its frequency has increased to 25.7% in CF patients in 2011 (CFF, 2017). Thus, the 
presence of the mecA gene, which encodes for methicillin resistance, in 70% of the S. aureus 
isolates in this study was anticipated.  Multiple hypotheses were proposed to explain how MRSA 
strains originated. One hypothesis is based on the association of the mec gene with genetically 
diverse lineages of S. aureus. Evolutionary genomic studies of S. aureus indicated that lateral 
gene transfer has greatly influenced the evolution of S. aureus (Fitzgerald 2001). The currently 
accepted hypothesis is that the mec gene has originated through horizontal gene transfer into S. 
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aureus at least five times. This implies that MRSA strains evolved multiple times in an 
independent manner and did not all originate from a single strain (Fitzgerald 2001).  
Upon the establishment of a MRSA infection within the lung airways of CF patients, it is 
extremely difficult to be cleared with the usage of antibiotics. As such, large epidemiologic 
studies have shown that the lung function of CF patients is more likely to decline with MRSA 
infections (Dasenbrook et al, 2010). The detection of MRSA strains in the lung airways of CF 
patients was also implicated with decreased chances of prolonged survival. Logically enough, 
patients with MRSA tend to be hospitalized more often than patients without MRSA. Further, it is 
also to be expected that the use of antibiotics is higher by patients with MRSA. Despite this, it 
was reported that only a few MRSA were resolved in regards to infections within CF patients. As 
present, there are no clearly outlined strategies to treat or clear MRSA infections (Dasenbrook et 
al, 2010). Typically, a combination of antibiotics is used to control MRSA infections such as 
vancomycin, linezolid, rifampicin, and others. Yet, the rare cases of MRSA clearance indicate 
that the eradication of MRSA may be possible through the use of antibiotics (Goss and 
Muhleback 2011).  Vancomycin has been considered a last resort antibiotic for the treatment of 
multiple-drug resistant bacteria. But in the recent years, vancomycin resistant S. aureus (VRSA) 
strains have emerged. The emergence of VRSA strains renders this last resort drug ineffective 
against S. aureus infections. Vancomycin resistance often overlaps with methicillin resistance in 
S. aureus. Thus, there is evident need for the development of new antibiotics that target S. aureus 
infections as well as new technologies that treat these infections in cystic fibrosis and other 
diseases caused by S. aureus. Likewise, more research efforts should center the focus on the 
mechanisms of resistance development in chronic infections.  
 S. aureus is a productive pathogen in terms of developing and acquiring resistance to 
antibiotics. This is demonstrated by the capability of the bacterium in employing a variety of 
mechanisms to combat the action of antibiotics. In order to understand how S. aureus resistance 
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to antibiotics occurs in the lungs of CF patients, testing was performed to determine the presence 
of antibiotic resistance genes within S. aureus isolates. These genes were present in some of the 
S. aureus patient isolates and were also in agreement with the phenotypic resistance observed by 
the Kirby-Bauer susceptibility tests. However, some isolates did not have any resistance genes 
present, yet they were resistant to antibiotics when tested with the Kirby-Bauer method. These 
findings were interesting due to the isolates having resistance to antibiotics phenotypically, 
despite the lack of resistance genes predicted to be contained by the isolate. As mentioned in 
chapter 3, the absence of resistance genes could be due to several factors including the possibility 
of the S. aureus isolates to carry other antibiotic resistance genes that were not included in our 
study. Also, this could be due to PCR not being sensitive, or even to a reduced priming efficiency 
due to the presence of mutations within the primer binding regions in these isolates 
(Standhouders, 2010). The absence of these resistance genes in phenotypically resistant S. aureus 
isolates could also suggest that S. aureus is using another mechanism to acquire resistance to 
antibiotics in the CF lung.   
S. aureus has the ability to rapidly resist antibiotics with novel mechanisms. There has 
not yet been an antibiotic that S. aureus could not defeat from the first antibiotic, penicillin, to the 
newest antibiotics, daptomycin and linezolid (Pantosti 2007). The mechanisms that S. aureus uses 
are diverse and complex, therefore, it is difficult to predict which mechanism S. aureus is 
utilizing to acquire resistance within the CF lung airways. The use of horizontal gene transfer is 
highly possible especially because the chromosomal cassette mec, or the vanA operon, have been 
acquired by S. aureus via this mechanism. Also, because the polymicrobial community in CF is 
highly dynamic; bacteria are continuously colonizing the lungs and dying. As a result, S.aureus 
has a great opportunity to obtain and uptake exogenous DNA from its surrounding environment. 
S. aureus also develops resistance by modifying the antimicrobial target to decrease the affinity 
of the antibiotic; this mechanism is used by MRSA and VRSA strains. It also can inactivate 
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antibiotics by enzymes; for example, the penicillinase enzyme inactivates penicillins and the 
aminoglycoside-modification enzyme inactivates aminoglycosides. Resistance to vancomycin and 
possibly other antibiotics such as daptomycin occurs via trapping of the antibiotics; whereas, 
efflux pumps are utilized to extrude antibiotics such as tetracyclines and fluoroquinolones 
(Pantosti 2007).  
S. aureus can also develop resistance through spontaneous mutations.  These spontaneous 
mutations have been well studied in resistance against rifampicin (Voss et al. 1994). Rifampicin 
has a great ability to penetrate through host tissues, thus it is often used in the treatment of deep 
or systemic infections. Rifampicin interferes with transcription initiation in bacteria. 
Therapeutically, rifampicin is often used in combination with other antibiotics as susceptible 
bacteria can develop rapid one-step mutations to become resistant against it. Resistance to 
rifampicin arises from mutations within the rpoB gene, which encodes for the RNA polymerase 
beta subunit. It has been reported that the majority of mutations occur within a short stretch of 
base pairs in the rpoB gene termed as the Rif region (Nicholson and Maughan 2002). In this 
study, amplification of the Rif region in S. aureus isolates was performed and was followed by 
sequence analysis.  Point mutations within the rpoB gene typically yield amino acid substitutions. 
The most common amino acid substitution from His to Asn (481HisàAsn) was identified within 
the scope of this study. The Pro to Ser (464ProàSer), His to Asn (481HisàAsn), Ala to Thr 
(477AlaàThr) and (473AlaàThr) substitutions were also confirmative of previously published 
rpoB mutations (Wichelhaus et al. 1999; Aubry-Damon 1998).  However, a couple of mutations 
observed in this study did not lead to an amino acid substitution. Silent mutations have been 
found to be present within the Rif region of the rpoB gene and have been reported in MRSA 
isolates (Tang et al. 2015).  Collectively, the rest of the mutations detected within this study were 
not previously described in S. aureus rpoB mutations, which could represent a novel 
identification of future mutations leading to S. aureus antibiotic resistances. In the past, higher 
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level of rifampicin resistance with MRSA has been documented in several studies (Tang et al. 
2015; Wichelhaus et al 1999).  However, the sample size in our study was small and that made it 
difficult to observe any patterns. This is partly due to the fact that the majority of the S. aureus 
isolates were already resistant to rifampicin. Considering that MRSA strains make up the majority 
of the S. aureus isolates in this study, we can conclude that there could be a relationship among 
MRSA prevalence and rifampicin resistance.  
 CF is one of the most studied genetic diseases and these research efforts have led to 
increasing the survival of CF patients. As of 2013, 49.7% of CF patients were over the age of 18 
compared to 29.2% in 1986 (CFF 2017). The clinical understanding of CF continues to evolve; 
yet much is to be understood about the complexity of this systemic disease. One of the most 
difficult challenges in managing CF infections is antibiotic resistance. This study clearly focused 
on the poorly described relationship between age and the development of resistance to antibiotics. 
Data from the Cystic Fibrosis Foundation Registry associated increased pulmonary exacerbation 
rates with older age. Pulmonary exacerbation in CF is a condition that requires hospitalization or 
use of IV antibiotics. As patients age, they experience more pulmonary exacerbations (CFF 
2014). The majority of CF studies focus on adult patients; that is because collecting CF sputa 
samples from children is difficult. Although the number of children and adolescents in our study 
is small, but the continuous collection and building of the repository of CF patient isolates will 
provide an avenue for further investigations related to age groups, including children. A linear 
relationship exists between increased exacerbation rates and aging of CF patients; this 
relationship in non-linear in children. In addition, as patients with CF age, the development of 
resistance to antibiotics becomes more frequent. This was documented in a longitudinal study 
conducted on Danish CF patients for over two decades; the study reported a significant rise in 
resistance to beta-lactam antibiotics as patients with CF became older (Goss 2006).  Therefore, 
the tested hypothesis within this study of adult CF patients exhibiting more resistance to 
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antibiotics than younger patients is supported. This is not only demonstrated by previous 
research, but also by the findings within this study of S. aureus obtained from adult patients 
having more resistance genes present when compared to adolescents and children countertypes. 
This data is important due to the fact that we are looking at both phenotypic and genotypic 
resistance profiles of CF patients. Most studies concerned with antibiotic resistance focus on the 
susceptibility of patient isolates to antibiotics only.  
 Currently, the focus is on developing new strategies to treat CF. We now understand that 
every patient with CF is unique and requires a treatment strategy that is specific to his/her 
condition and the push for these individualized treatments should be a priority to researchers and 
health care facilities.  The development of new antibiotics and innovative technologies that treat 
typical to chronic infections is also crucial. Resistance to antibiotics is a major medical concern 
and will be the major cause of mortality worldwide if research is not focused on averting 
antimicrobial resistance. A lot is to be understood about S. aureus infections in the CF lung 
specially regarding the acquisition of antibiotic resistance. The absence of resistance genes raises 
many questions related to the mechanisms that S. aureus is using to become resistant and persist 
in the lungs of patients with CF. This study did not include all of the resistance genes produced 
by S. aureus; thereby leaving a window open for future investigations. For instance, genes such 
as aac(6)/aph(2), aph(3), and ant(4) encode for aminoglycoside resistance were not included 
(Duran et al. 2012). Several genes also encode for macrolide resistance that were not tested for 
within the scope of this investigation include: vgaB, vgbB, vatC, and msrB (Gerard et al. 1999). 
Other questions raised by the findings include: Is S. aureus using horizontal gene transfer to 
acquire resistance? Or is the cause of resistance genetic mutations? Or is it modifying enzymes 
and target locations? Quite possibly, S. aureus could be utilizing a combination or rather a novel 




V.a. Future Directions 
The work discussed in this thesis serves as a platform for several forthcoming research 
projects. More research is required to understand the cause of S. aureus resistance to antibiotics. 
In the future it is important to continue the collection of CF sputa samples from the CF clinic to 
increase the sample size and further confirm the trends seen in this study. It is an urgent necessity 
to expand the number of antibiotic resistance genes to include the genes mentioned above, as they 
could be present in the S. aureus isolates. It is also worthwhile to repeat the PCR using different 
sets of primers for the nine antibiotic resistance genes included in this study. Using other sets of 
primers that have been published for the same genes might rule out the possibility of negative 
PCR due to mutations or gene truncation as they might bind to different locations within the gene. 
In addition, designing primers that specifically target these genes instead of relying on published 
primers can be helpful in solving the puzzle of no amplification of resistance genes.  The 
presence of antibiotic resistance genes is only one simple step towards the understanding of 
antibiotic resistance of S. aureus during colonization and infection within the lungs of CF 
patients. As demonstrated by this investigation, the presence of known antibiotic resistance-
encoding genes does not determine as to gene and ultimate protein functionality. As such, it is 
essential to follow the initial conventional PCR screening for antibiotic resistance genes with 
gene expression with modern in vitro biochemical methods. 
Our findings also emphasize that S. epidermidis plays an important role in human 
disease. As previously stated, S. epidermidis is now accountable for many nosocomial infections 
and it also provides a reservoir of antibiotic resistance genes to S. aureus. More importantly, 
methicillin resistant S. epidermidis strains are highly transmissible. Therefore, it is important to 
focus on understanding both the commensal and infectious roles of S. epidermidis in CF in terms 
of pathogen-pathogen interactions. It is important to start with sequencing the S. epidermidis 
isolates. Then, look for the presence of antibiotic resistance genes among these isolates along 
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with conducting antibiotic susceptibility tests. Next, determine how the presence of S. aureus and 
S. epidermidis in the same environment affects susceptibility to antibiotics.  
This study also initiated a basic understanding of the resistance of S. aureus isolates to 
rifampicin. Novel mutations were detected within this data set, and these mutations need to be 
further studied to see if the amino acid substitutions they caused affect the level of resistance to 
rifampicin. This is important because resistance to rifampicin is often associated with increased 
MRSA and VRSA. It is also important to investigate the relationship between rifampicin 
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Figure 10 shows the streaking of isolate 12315E. The colored arrows point to colonies of 
different sizes. In particular, 3 S. aureus strains were selected from this one patient isolate (each 
color points to a different strain) and they were named as 12315E (1), 12315E(2), and 12315E 
(3). Each one of these strains was tested as a separate isolate from this patient. 
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Figure 11: Complete resistance to antibiotics MET, ERY, and KN shown in the top image as 
no zones of clearance around the discs were observed. The bottom image shows the susceptibility 
to GM, TOB, and STM, which were indicated by the formation of clearance zones around the 








Appendix C: Gel visualization of resistance genes 
 
 
Figure 12: The gel images show the amplification results of antibiotic resistance genes in 
some of the S. aureus isolates and the sizes of the amplified genes. The images show both 




Appendix D: Diversity of S. aureus isolates within a single patient 
Figure 13: Diversity of S. aureus isolates within patient 11614D  
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Figure 13 shows the diversity in antibiotic resistance of S. aureus isolates within a single CF 
patient. One child patient and one adult patient were randomly selected. Fifteen random colonies 
were selected (each colony representing an isolate from that patient), and then performed Kirby-
Bauer susceptibility tests. The plates in Figure 13 are the results of the child patient 11614D and 
they show that there was no difference in the zones of clearance around the discs. The same 
results were observed in the adult patient. This indicates that there is no diversity in antibiotic 
resistance of S. aureus isolates obtained from a single CF patient.   
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